Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with Bortezomib Regimens in NDMM
NCT02513186Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of isatuximab in multiple myeloma (MM) (2 cohorts), sponsored by Sanofi. Primary endpoints: Dose-Limiting Toxicities at 6 weeks, Overall Response Rate at 34 weeks and 1 more. Started Sep 2015; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02513186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513186.